NCT01672775View on ClinicalTrials.gov

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 18, 2012

Primary Completion Date

February 21, 2017

Study Completion Date

February 21, 2017

Conditions
Carcinoma, Renal CellRenal Cell Carcinoma of Papillary HistologyRenal Cell Carcinoma With Clear Cell HistologyRenal Cell Carcinoma With Non-Clear Cell Histology
Interventions
DRUG

AGS-16C3F

intravenous (IV) infusion

Trial Locations (9)

10065

Site US00002 Memorial Sloan-Kettering Cancer Center, New York

14263

Site US00004 Roswell Park Cancer Institute, Buffalo

48109

Site US00005 University of Michigan Medical Center, Ann Arbor

48201

Site US00003 Karmanos Cancer Institute, Detroit

98109

Site US00001 Seattle Cancer Care Alliance, Seattle

T6G 1Z2

Site CA00006 Cross Cancer Institute, Edmonton

V5Z 4E6

Site CA00008 British Columbia Cancer Agency, Vancouver

N6A 4L6

Site CA00009 London Health Sciences Centre, London

H3T 1E2

Site CA00007 Jewish General Hospital, Montreal

Sponsors

Lead Sponsor

Agensys, Inc.
All Listed Sponsors
lead

Agensys, Inc.

INDUSTRY

NCT01672775 - A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology | Biotech Hunter | Biotech Hunter